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Most patients with severe atopic dermatitis have elevated 
serum IgE levels, but there has been little research into 
IgE as a predictive biomarker in long-term disease out-
come. The aim of this study was to evaluate the predicti-
ve value of IgE and other factors in patients with atopic 
dermatitis in a university clinic setting. There were 169 
eligible patients (14–78 years) with a mean follow-up of 
4.15 years. High baseline IgE (≥ 10,000 IU/ml) was the 
most important patient-related factor for a poor long-
term outcome, being negatively associated with good tre-
atment response (odds ratio (OR) 0.062, p = 0.002). Only 
14.3% of patients with this high baseline IgE achieved 
a good treatment response in follow-up, compared with 
79.7% in patients with lower (< 1,000 IU/ml) IgE values 
(p < 0.001). Serum total IgE may provide an easily mea-
surable way to predict long-term outcome, and to help 
to select those patients in need of closer follow-up. Key 
words: atopic dermatitis; immunoglobulin E; biomarker; 
treatment response.
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Atopic dermatitis (AD) is a chronic, relapsing, and 
intensely pruritic inflammatory skin disease and one 
of the most frequent inflammatory skin diseases (1, 2). 
Patients with AD often have comorbidities, including 
food allergies, asthma and allergic rhinoconjunctivitis 
(3–5). The pathogenesis of AD is complex, including 
epidermal barrier dysfunction and immunological events, 
both of which contribute to the inflammatory condition 
of the skin (6, 7). In AD the clinical phenotype may be 
the result of many distinct genetic variations interacting 
with numerous environmental factors (2, 3). In particular, 
there is a strong association between filaggrin (FLG) gene 
loss-of-function mutations and AD; approximately 30% 
of patients with AD have a loss-of function mutation in 
the FLG gene (8–10).
A biomarker is a characteristic that is objectively 
measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharma-
cological responses to a therapeutic intervention (7). 
Objectively measurable biomarkers would present a 
valuable tool in AD. These biomarkers may help with 
the choice of treatment regimen, in the prediction of 
treatment response, and may provide information on di-
sease progression. FLG mutations have been suggested 
as a possible biomarker in AD (2, 11). Other proposed 
possible biomarkers include serum levels of CD30, 
macrophage-derived chemokine (MDC), interleukins 
12, 16, 18 and 31, and thymus and activation-regulated 
chemokine (TARC), serum eosinophil cationic protein 
(ECP), total eosinophil count, and T helper 2 cell cyto-
kines CCL17, CCL22, CCL27 (12–17). Serum total IgE 
is another possible biomarker: most AD patients with 
severe disease have elevated total IgE levels and recent 
studies have shown a significant correlation between 
decreased disease activity, including normalization of 
Th2 polarity, and a decrease in total IgE levels during 
follow-up (18–21). There has been little research into 
the use of total IgE as a predictive biomarker for long-
term outcome in AD.
The primary aim of this study was to examine the 
use of a possible biomarker – serum total IgE – and 
other patient- or treatment-related factors as outcome-
predicting factors of long-term treatment response in 
AD. We investigated associations between baseline IgE 
values and the change in IgE levels during follow-up, 
and the clinical course of AD and treatment response on 
maintenance-type topical treatment. We also analysed 
other patient- and treatment-related factors in relation 
to the treatment results in order to evaluate factors 
associated with long-term outcome and possible risk 
factors for a poor outcome
MATERIAL AND METHODS
This study is part of an ongoing AD genetics study in Finnish 
patients, which started on 1 June 2011. This is a retrospective 
study with follow-up data prior to the baseline of the aforemen-
tioned AD genetics study. The baseline for this study was the first 
visit of study subjects to the specialized AD clinic at the Skin 
and Allergy Hospital of Helsinki University Central Hospital, 
a referral centre for dermatology and allergology. The endpoint 
was the enrolment visit for the AD genetics study. The study 
participants are patients with AD referred to the specialized AD 
clinic by general practitioners or dermatologists due to difficulties 
in obtaining adequate treatment results or the severity of their 
disease. The study was approved by the local ethics committee.
Data prior to the AD genetics study were gathered from all 
eligible subjects. Patients with less than one year of follow-up 
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and patients ≤ 13 years of age were excluded. In total, data 
from 169 patients were eligible for analysis. Data were col-
lected from electronic patient records from January 1, 2002 
onwards. Baseline information on IgE levels (measured using 
CAP system-specific IgE fluorometric enzyme immunocapture 
assay), clinical AD severity, previous and/or concomitant medi-
cations and other relevant information was collected. Clinical 
severity of AD at baseline was obtained from patient charts 
based on a clinical examination by a dermatologist. Patients 
were divided into 3 groups based on clinical severity: mild 
(investigator’s global assessment (IGA) 1–2), moderate (IGA 
3) and severe (IGA 4–5). 
Patients enrolled in the AD genetics study were interviewed 
and examined by a dermatologist. The data from interviews 
were confirmed from patient records when necessary and 
applicable. Data were collected on demographic factors, atopic 
manifestations in close relatives, other manifestations of atopy 
(rhinitis, conjunctivitis, asthma, food allergy), current and past 
treatment regimens on AD, current medications, history of oral 
medications used for AD, hospitalization because of AD, age 
of onset, smoking (prior and current), skin-prick testing, patch-
test diagnosed contact allergies, and history of herpes simplex 
virus (HSV) infections. Clinical symptoms were assessed and 
graded again by a dermatologist. Symptoms of atopic hand and/
or palmar eczema were assessed separately. The data gathered 
from these interviews and clinical examinations were used as 
a primary source for endpoint data.
Treatment response was evaluated at the endpoint. “Com-
plete remission” was defined as the absence of AD symptoms 
in previously symptomatic patients, and “good response” was 
defined as alleviation of symptoms at the endpoint compared 
with baseline, grading of dermatitis being mild or clear at the 
endpoint. Adherence to treatment was also assessed on a scale 
of 1–3 (poor, average, good), based on how well the patient had 
been following the maintenance treatment regimen.
Topical treatments for patients in this study were either 
maintenance treatment with topical tacrolimus or maintenance 
treatment with either a combination of topical tacrolimus and 
topical corticosteroids, or topical corticosteroids alone. Patients 
were visiting a specialized AD clinic and had received a long-
term treatment plan from a dermatologist. They also received 
hands-on training for adequate topical therapy regimens from 
a nurse, when necessary. In some cases the treatment was ini-
tiated with a few daily appointments with a nurse to strengthen 
adherence. 
Statistical analyses were performed to identify factors asso-
ciated with, or predictive for, both a good treatment response 
and complete remission. Univariate and adjusted odds ratios 
(OR) with 95% confidence intervals (95% CI) were calculated 
using logistic regression models. Factors indicating an associa-
tion (p-value ≤ 0.10) in the univariate analyses were included 
as covariates in the multivariate analysis for adjusted ORs. The 
variables eligible for the multivariate logistic regression model 
were tested for significant interactions. The non-parametric 
Wilcoxon signed-rank test was used to calculate p-values for 
the changes in total IgE and the clinical severity of AD between 
the baseline and the end of follow-up. Studies on analyses per-
formed with immunological data, such as IgE and interleukin 4, 
have shown that these markers tend to have a positively skewed 
distribution. Conducting analyses with data transformed to a 
logarithmic scale has been shown to illustrate a better measure 
of central tendency, as data analysed with a logarithmic scale 
are less subjected to distortion by the unusually large values in 
the tail of the positively skewed distribution of the data (22). 
Based on this information, IgE values were analysed with the 
logarithmic scale. All statistical analyses were performed using 
SPSS 21 and SPSS 22 for Mac (IBM, Chicago, IL, USA).
RESULTS
Patients and serum total IgE
There were 169 eligible patients (age range 14.0–78.1 
years (mean 33.0 years); 59% women, 41% men). Mean 
follow-up time was 4.15 years (range 1.0–10.4 years). 
Most of the subjects had a strong atopic diathesis with 
high levels of allergic rhinitis, allergic conjunctivitis, 
food allergies, and asthma, and high IgE values (me-
dian 1,501 at baseline) (Table I). 
At baseline, 71.0% of patients had moderate–severe 
AD symptoms. By the end of follow-up this proportion 
had decreased to 29.7%. The proportion of patients 
with clear-mild symptoms was 29.0% at baseline and 
increased to 70.2% (p < 0.001) during follow-up.
Median total IgE values were 1,501 IU/ml (mean 
5,670 IU/ml) at baseline and 1,130 IU/ml (mean 5,121 
IU/ml) at end of follow-up (p < 0.001). Seventy-nine 
percent of patients with good adherence had good 
response or total clearance vs. 53% of patients with 
worse adherence (p = 0.05). Assessed adherence was 
associated with the IgE response: 45% of patients with 
good adherence had a significant (> 50%) IgE decrease 
vs. 25% of patients with poor adherence (p = 0.02).
Factors associated with long-term outcome
Predictive factors for a good treatment response and for 
complete remission were assessed separately. Sex, symp-
toms of allergic rhinitis or conjunctivitis, food allergy, 
hand eczema (neither dorsal or palmar), any positive 
reactions in skin-prick testing, prick-test positivity for 
peanuts, a positive history of HSV infection, systemic 
immunosuppressive medication for indications other 
than AD, current smoking or a history of smoking, age 
of onset, main topical therapy used, and regular use of 
oral antihistamines/montelukast showed no associations 
with either a good treatment response or a total remission 
in univariate analysis. Younger age and milder clinical 
baseline severity showed an association with a good 
treatment response, but not with complete remission. 
Asthma, baseline total IgE, and the presence of patch-test 
diagnosed contact allergies were negatively associated 
with both a good treatment response and a complete 
remission of AD symptoms in univariate analyses.
After adjusting the multivariate analyses, the presence 
of contact allergies and high baseline IgE values ≥ 10,000 
IU/ml remained risk factors for a poor long-term outcome 
and were statistically significantly negatively associated 
with a good treatment response (OR 0.162 and 0.062, 
respectively), and with complete remission (OR 0.287 
and 0.158, respectively) (Table II). Only 16.5% of pa-
tients with diagnosed contact allergies achieved complete 
remission and 34.5% showed a good treatment response. 
In patients without contact allergies the proportions were 
vs. 45.4% and 71.3%, respectively. In patients with base-
line IgE ≥ 10,000 IU/ml proportions achieving complete 
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remission or a good treatment response were only 8.7% 
and 14.3%, compared with 51.6% and 79.7% in patients 
with IgE < 1,000 IU/ml, and 36.9% and 58.1% in patients 
with IgE 1,000–10,000 IU/ml, respectively.
DISCUSSION
IgE is the scarcest of serum immunoglobulins, constitu-
ting only 0.0005% of the total free serum immunoglo-
bulins in non-atopic adults, but the presence of elevated 
levels of serum total IgE is strongly associated with 
atopic disease (23, 24). Class switch to IgE in B cells is 
induced by allergen contact in conjunction with T-cell 
interaction and a T-helper type 2 cell polarized cytokine 
microenvironment (25). The half-life of free serum IgE 
is only 2–3 days and it has to be produced continuously 
in order to maintain its serum levels (26). Little is known 
about the source of IgE. It has been proposed that allergy 
Table I. Patient demographics and other variables
Variable n (%) Variable n (%)
Age, baseline Hand eczema (any)
0–20 years 37 (21.9) No 38 (22.5)
> 20–40 years 83 (49.1) Yes 120 (71.0)
> 40 years 49 (29.0) Not stated 11 (6.5)
Range 14.0–78.1; Mean 33.0 Palmar hand eczema
Sex No 68 (40.2)
Female 100 (59.2) Yes 38 (22.5)
Male 69 (40.8) Not stated 63 (37.3)
Origin Food allergies
Caucasian 159 (94.1) No 43 (25.4)
Other 8 (4.7) Yes 121 (71.6)
Not stated 2 (1.2) N/S 5 (3.0)
Follow-up, years Range 1.00–10.43; Mean 4.15 Diagnosed contact allergies and the most common allergens
Baseline severity No 97 (57.4)
Remission/mild 47 (27.8) Yes 31 (18.3)
Moderate 46 (27.2) Not stated 41 (24.3)
Severe 69 (40.8) Nickel 11 
Not stated 7 (4.1) Perfumes 11 
Baseline total IgE Cobalt 5 
0–99 IU/ml 13 (7.7) Topical antimicrobials/antiseptics 5 
100–999 IU/ml 51 (30.2) Chrome 3 
1,000–9,999 IU/ml 66 (39.1) Lanolin 2 
≥ 10,000 IU/ml 23 (13.6) Preservatives 2 
Not stated 16 (9.5); Range 3–98,100 Current smoking
Mean 5,670; Median 1,501 No 124 (73.4)
Topical therapy Yes 4 (24.9)
TCS or TCS + tacrolimus 53 (31.4) Not stated 3 (1.8)
Tacrolimus monotherapy 116 (68.6) History of smoking
Age of onset No 96 (56.8)
≤ 2 years 121 (71.6) Yes, < 5 years 11 (6.5)
> 2 years 34 (20.1) Yes, > 5 years 45 (26.6)
Not stated 14 (8.3) Not stated 17 (10.1)
Asthma Regular use of inhalation corticosteroids
No 75 (44.4) No 137 (81.1)
Yes 84 (49.7) Yes 31 (18.3)
Not stated 10 (5.9) Not stated 1 (0.6)
Allergic rhinitis symptoms Regular use of oral antihistamine/montelukast
No 27 (16.0) No 153 (90.5)
Yes 140 (82.8) Yes 15 (8.9)
Not stated 2 (1.2) Not stated 1 (0.6)
Allergic conjunctivitis symptoms Oral antimicrobial medications due to AD
No 35 (20.7) No 39 (23.1)
Yes 132 (78.1) Yes 124 (73.4)
N/S 2 (1.2) Not stated 6 (3.6)
Skin-prick test positivities Current immunosuppressive medication (indication other than AD)
No 6 (3.6) No 162 (95.9)
Yes, any 97 (57.4) Yes 6 (3.6)
Yes, peanut 55 (32.5) Not stated 1 (0.6)
Not stated 66 (39.1) Adherence to treatment (endpoint evaluation)
History of HSV infections Poor 19 (11.2)
No 92 (54.4) Average 53 (31.4)
Yes 44 (26.0) Good 62 (36.7)
Not stated 33 (19.5) Not stated 35 (20.7)
AD: atopic dermatitis; IgE: immunoglobulin E; IU: International Units; TCS: topical corticosteroids; HSV: herpes simplex virus.
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effector organs (e.g. the lungs and the nasal mucosa) may 
be important sites of IgE production in allergic patients. 
IgE-producing cells have also been found in the blood, 
but their numbers are extremely low (27). 
Previous studies have shown that total IgE levels are 
elevated in the majority of AD patients with moderate-
to-severe disease, and a correlation between IgE levels 
and AD severity has been suggested in some studies 
(18, 19), but the results are partly conflicting (15, 28). 
Total IgE values at the age of 6–18 months seem to 
predict the subsequent visible AD at the age of 5 years 
in children (29). 
In this study the most important factor predicting com-
plete remission of AD and a good treatment response on 
the maintenance type of treatment, was serum total IgE. 
There was no correlation between baseline clinical seve-
rity of AD symptoms (IGA) and baseline total IgE in the 
patients studied. This may be because they were tertiary 
referral centre patients with a strong atopic diathesis who 
had already been treated by general practitioners and 
private dermatologists at baseline prior to follow-up in 
the specialized AD clinic. Also, due to the flaring nature 
of AD, a single-point evaluation of the clinical symp-
toms is often inadequate in defining the severity of the 
disease. In our data, the total IgE level predicted long-
term treatment response much better than the baseline 
clinical picture. This finding is useful, as measurement 
of total IgE is easy and inexpensive and could be used 
to select patients who require closer follow-up in order 
to achieve a sufficient treatment response. 
Median total IgE levels of the study patients de-
creased significantly during follow-up, showing an 
overall IgE response to the topical maintenance type of 
treatment. In patients with IgE values <10,000 IU/l at 
baseline, there was a trend towards a greater decrease in 
total IgE in patients who achieved complete remission, 
which is in concordance with previous studies showing 
a total IgE decrease in responders (30). Adherence to 
treatment appears to explain most of this trend, but it 
is a highly subjective variable in a non-blinded setting 
when assessed at the endpoint. No routine screening 
for parasite infections was done in these patients due to 
the very low total incidence (<10/100,000) of parasitic 
infections in Finland (31, 32). Hyper-IgE syndrome 
was clinically excluded in all patients with remarkably 
elevated IgE values.
In addition, contact sensitization appears to predict 
a poor outcome in long-term follow-up. At first glance 
this may seem surprising, since contact sensitization 
has been considered to be Th1 polarized in contrast to 
the Th2 polarization in AD, although recently it has 
been shown that atopic individuals may also have Th2 
polarization in cases of contact sensitization (33). Also, 
it appears plausible that the larger the skin barrier defect, 
the greater the risk of contact sensitization (34). This 
group of patients may therefore represent a subgroup of 
AD patients with a more extensive skin barrier defect, 
which may explain the poor treatment response and 
long-term outcome. The mean total IgE values were 
slightly lower in patients with contact allergies, but 
regarding the prevalence of hand eczema or any other 
factor of the baseline clinical picture, these patients did 
not differ from patients with no contact sensitization. It 
is therefore unlikely that the more extensive patch-testing 
of patients with more severe symptoms would explain 
the association of contact allergies with poor outcome. 
Most (77%) of the patients with contact allergies were 
female, which is in concordance with previous studies 
concerning nickel as a common allergen (35); however, 
sex itself was not associated with outcome. 
It is noteworthy that the proportion of patients with 
remission or, at most, mild AD symptoms, at the end 
of follow-up was 70%, indicating that good treatment 
results are possible, even in this kind of selected pa-
tient population with mostly moderate–severe AD and 
a high atopic diathesis, with topical maintenance type 
of therapy. None of the study patients were on systemic 
treatments at the end of follow-up and only a few had a 
history of systemic treatments. The effect of systemic 
medication in this study population can therefore be 
considered minor.
The retrospective setting and the selected tertiary 
referral centre study population were limitations of this 
study. The strengths of this study were the long follow-
up time, the relatively large number of patients, and the 
real-life clinical setting.
These results have yet to be confirmed in a larger, 
prospective setting. Serum total IgE appears to be a 
promising biomarker in the treatment of AD, predicting 
long-term outcome. The association of delayed cell-
mediated hypersensitivity with poor long-term outcome 
in AD may reflect greater, more treatment-resistant, and 
possible inflammation-independent defects in the skin 
barrier, increasing susceptibility to contact allergies.
Table II. Associations of variables with long-term outcome, 
adjusted analysis
Variable
Good treatment response Complete remission
Odds ratio p-value Odds ratio p-value
Baseline total IgE
0–999 IU/ml 1 1
1,000–9,999 IU/ml 0.202 0.005 0.462 0.091
≥10,000 IU/ml 0.062 0.002 0.158 0.031
Contact allergies
No 1 1
Yes 0.162 0.007 0.287 0.048
Age, years 0.972 0.129 1.009 0.572
Asthma
No 1 1
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